

Express Mail Label No.: EN 1847031US  
Date of Deposit: February 5, 2001

Attorney Docket No. 21509-042



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Lee *et al.*  
ASSIGNEE: President and Fellows of Harvard College  
SERIAL NUMBER: 09/503,596 EXAMINER: M. Schmidt  
FILING DATE: February 11, 2000 ART UNIT: 1635  
FOR: INHIBITING FORMATION OF ATHEROSCLEROTIC LESIONS

#6/pre  
A  
w/seq.  
listing

Assistant Commissioner for Patents  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Prior to examination, please amend the application as follows.

***In the Specification:***

On page 12, line 14, delete the letters "AFABP" from the first line of SEQ ID NO:5.

**REMARKS**

The specification was amended to correct a typographical error. The first five letters "AFABP" have been deleted from SEQ ID NO:5, which appears in Table 4 (page 12, line 14) of the specification. These letters represent an abbreviation of the name of the protein (adipocyte fatty acid binding protein; AFABP) and were inadvertently inserted prior to the actual amino acid sequence of the AFABP protein. The actual amino acid sequence begins with the letters "MCDAFV...." "AFABP" is not an amino acid sequence and is not part of SEQ ID NO:5.

No new matter has been added by this amendment.

**CONCLUSION**

On the basis of the foregoing amendments and remarks, Applicants submit that the pending claims are in condition for allowance. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact either of the undersigned at the telephone number provided below.